<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1003257027
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EMILOK 20MG CAPSULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OMEPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        37.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TOWA PHARMACEUTICAL EUROPE S L" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TOWA PHARMACEUTICAL EUROPE S L
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 423]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            MANAYER NAJD TRADING MEDICAL NEEDS CO.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLOBAL PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Emilok contains the active substance omeprazole. It belongs to a group of medicines called &lsquo;proton pump inhibitors&rsquo;. They work by reducing the amount of acid that your stomach produces.</p><p>Emilok is used to treat the following conditions:</p><p>In adults:</p><p>&bull; &lsquo;Gastro-oesophageal reflux disease&rsquo; (GORD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain,</p><p>inflammation and heartburn.</p><p>&bull; Ulcers in the upper part of the intestine (duodenal ulcer) or stomach (gastric ulcer).</p><p>&bull; Ulcers which are infected with bacteria called &lsquo;Helicobacter pylori&rsquo;. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</p><p>&bull; Ulcers caused by medicines called NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).</p><p>Emilok can also be used to stop ulcers from forming if you are taking NSAIDs.</p><p>&bull; Too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome).</p><p>In children:</p><p>Children over 1 year of age and weighing 10 kg or more:</p><p>&bull; &lsquo;Gastro-oesophageal reflux disease&rsquo; (GORD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.</p><p>In children, the symptoms of the condition can include the return of stomach contents into the mouth (regurgitation), being sick (vomiting) and poor weight gain.</p><p>Children and adolescents over 4 years of age:</p><p>&bull; Ulcers which are infected with bacteria called &lsquo;Helicobacter pylori&rsquo;. If your child has this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Emilok</p><p>&bull; if you are allergic to omeprazole or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull; if you are allergic to medicines containing other proton pump inhibitors (eg pantoprazole, lansoprazole, rabeprazole, esomeprazole).</p><p>&bull; if you are taking a medicine containing nelfinavir (used for HIV infection).</p><p>Do not take Emilok if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Emilok.</p><p>Warnings and precautions</p><p>Emilok may hide the symptoms of other diseases. Therefore, if any of the following happen to you before you start taking Emilok or while you are taking it, talk to your doctor straight away:</p><p>&bull; You lose a lot of weight for no reason and have problems swallowing.</p><p>&bull; You get stomach pain or indigestion.&nbsp;&nbsp;&nbsp; &bull; You begin to vomit food or blood.</p><p>&bull; You pass black stools (blood-stained faeces).</p><p>&bull; You experience severe or persistent diarrhoea, as Emilok has been associated with a small increase in infectious diarrhoea.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; You have severe liver problems.</p><p>&bull; You have ever had a skin reaction after treatment with a medicine similar to Emilok that reduces stomach acid.</p><p>&bull; You are due to have a specific blood test (Chromogranin A).</p><p>If you take Emilok on a long-term basis (longer than 1 year) your doctor will probably keep you under regular surveillance. You should report any new and exceptional symptoms and circumstances whenever you see your doctor.</p><p>Taking a proton pump inhibitor like Emilok, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p>If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with Emilok . Remember to also mention any other illeffects like pain in your joints.</p><p>Subacute cutaneous lupus erythematosus (SCLE): Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping this medication. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p>Children</p><p>Some children with chronic illnesses may require long-term treatment although it is not recommended. Do not give this medicine to children under 1 year of age or &lt; 10 kg.</p><p>Other medicines and Emilok</p><p>Tell your doctor or pharmacist if you are taking, have recently taken any other medicines or might take any other medicines. This is because Emilok can affect the way some medicines work and some medicines can have an effect on Emilok.</p><p>Do not take Emilok if you are taking a medicine containing nelfinavir (used to treat HIV infection).</p><p>Tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&bull; Ketoconazole, itraconazole, posaconazole or voriconazole (used to treat infections caused by a fungus)</p><p>&bull; Digoxin (used to treat heart problems)</p><p>&bull; Diazepam (used to treat anxiety, relax muscles or in epilepsy)</p><p>&bull; Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to monitor you when you start or stop taking omeprazole</p><p>&bull; Medicines that are used to thin your blood, such as warfarin or other vitamin K blockers. Your doctor may need to monitor you when you start or stop taking omeprazole</p><p>&bull; Rifampicin (used to treat tuberculosis)&nbsp;&nbsp;&nbsp; &bull; Atazanavir (used to treat HIV infection)</p><p>&bull; Tacrolimus (in cases of organ transplantation)</p><p>&bull; St John&rsquo;s wort (Hypericum perforatum) (used to treat mild depression)</p><p>&bull; Cilostazol (used to treat intermittent claudication)</p><p>&bull; Saquinavir (used to treat HIV infection)</p><p>&bull; Clopidogrel (used to prevent blood clots (thrombi)&nbsp; &bull; Erlotinib (used to treat cancer)</p><p>&bull; Methotrexate (a chemotherapy medicine used in high doses to treat cancer) &ndash; if you are taking a high dose of methotrexate, your doctor may temporarily stop your Emilok treatment.</p><p>If your doctor has prescribed the antibiotics amoxicillin and clarithromycin as well as omeprazole to treat ulcers caused by Helicobacter pylori infection, it is very important that you tell your doctor about any other medicines you are taking.</p><p>Emilok with food and drink:</p><p>You can take your capsules with food or on an empty stomach (see section 3) .</p><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a</p><p>baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Omeprazole is excreted in breast milk but is not likely to influence the child when</p><p>therapeutic doses are used. Your doctor will decide whether you can take Emilok if you are</p><p>breast-feeding.</p><p>Driving and using machines: Emilok is not likely to affect your ability to drive or use any tools or machines. Side effects such as dizziness and visual disturbances may occur (see section 4). If affected, you should not drive or operate machinery.</p><p>Emilok contains lactose&nbsp; and sucrose</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will tell you how many capsules to take and how long to take them for. This will depend on your condition and how old you are.</p><p>The usual doses are given below.</p><p>Adults: To treat symptoms of GORD such as heartburn and acid regurgitation:</p><p>&bull; If your doctor has found that your food pipe (gullet) has been slightly damaged, the recommended dose is 20 mg once a day for 4-8 weeks. Your doctor may tell you to take a dose of 40 mg for a further 8 weeks if your gullet has not yet healed.</p><p>&bull; The recommended dose once the gullet has healed is 10 mg of omeprazole once a day.</p><p>&bull; If your gullet has not been damaged, the usual dose is 10 mg of omeprazole once a day.</p><p>To treat ulcers in the upper part of the intestine (duodenal ulcer):</p><p>&bull; The recommended dose is 20 mg once a day for 2 weeks. Your doctor may tell you to take the same dose for a further 2 weeks if your ulcer has not yet healed.</p><p>&bull; If the ulcer does not fully heal, the dose can be increased to 40 mg once a day for 4 weeks.</p><p>To treat ulcers in the stomach (gastric ulcer):</p><p>&bull; The recommended dose is 20 mg once a day for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your ulcer has not yet healed.</p><p>&bull; If the ulcer does not fully heal, the dose can be increased to 40 mg once a day for 8 weeks.</p><p>To prevent the duodenal and stomach ulcers from coming back:</p><p>&bull; The recommended dose is 10 mg or 20 mg of omeprazole once a day. Your doctor may increase the dose to 40 mg once a day.</p><p>To treat duodenal and stomach ulcers caused by NSAIDs (Non-Steroidal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti Inflammatory Drugs):</p><p>&nbsp;&bull; The recommended dose is 20 mg once a day for 4&ndash;8 weeks.</p><p>To prevent duodenal and stomach ulcers if you are taking NSAIDs:</p><p>&bull; The recommended dose is 20 mg once a day.</p><p>To treat ulcers caused by Helicobacter pylori infection and to stop them coming back:</p><p>&bull; The recommended dose is 20 mg omeprazole twice a day for one week.</p><p>&bull; Your doctor will also tell you to take two antibiotics among amoxicillin, clarithromycin and metronidazole.</p><p>To treat too much acid in the stomach caused by a growth in the pancreas (Zollinger-</p><p>Ellison syndrome):</p><p>&nbsp;&bull; The recommended dose is 60 mg daily.</p><p>&bull; Your doctor will adjust the dose depending on your needs and will also decide how long you need to take the medicine for.</p><p>Use in children and adolescents:</p><p>To treat symptoms of GORD such as heartburn and acid regurgitation:</p><p>&bull; Children over 1 year of age and with a body weight of more than 10 kg may take omeprazole. The dose for children is based on the child&rsquo;s weight and the doctor will decide the correct dose.</p><p>To treat ulcers caused by Helicobacter pylori infection and to stop them coming back:</p><p>&bull; Children aged over 4 years may take omeprazole. The dose for children is based on the child&rsquo;s weight and the doctor will decide the correct dose.</p><p>&bull; Your doctor will also prescribe two antibiotics called amoxicillin and clarithromycin for your child.</p><p>Taking this medicine</p><p>&bull; It is recommended that you take your capsules in the morning.</p><p>&bull; You can take your capsules with food or on an empty stomach.</p><p>&bull; Swallow your capsules whole with half a glass of water. Do not chew or crush the capsules. This is because the capsules contain coated pellets which stop the medicine from being broken down by the acid in your stomach. It is important not to damage the pellets.</p><p>What to do if you or your child has trouble swallowing the capsules</p><p>&bull; If you or your child have trouble swallowing the capsules:</p><p>- Open the capsules and swallow the contents directly with half a glass of water or put the contents into a glass of still (non-fizzy) water, any acidic fruit juice (e.g. apple, orange or pineapple) or apple sauce.</p><p>- Always stir the mixture just before drinking it (the mixture will not be clear). Then drink the mixture straight away or within 30 minutes.</p><p>- To make sure that you have drunk all of the medicine, rinse the glass very well with half a glass of water and drink it. Do not use milk or fizzy water. The solid pieces contain the medicine - do not chew or crush them.</p><p>If you take more Emilok than you should: If you take more Emilok than prescribed by your doctor, talk to your doctor or pharmacist straight away.</p><p>If you forget to take Emilok: If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Emilok: Do not stop taking Emilok without first talking to your doctor or pharmacist.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you notice any of the following rare but serious side effects, stop taking Emilok and contact a doctor immediately:</p><p>&bull; Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or difficulties in swallowing (severe allergic reaction).</p><p>&bull; Reddening of the skin with blisters or peeling. There may also be severe blisters and bleeding in the lips, eyes, mouth, nose and genitals. This could be &lsquo;Stevens-Johnson syndrome&rsquo; or &lsquo;toxic epidermal necrolysis&rsquo;.</p><p>&bull; Yellow skin, dark urine and tiredness which can be symptoms of liver problems.</p><p>Other side effects which may occur are listed below in groups according to the frequency.</p><p>Please tell your doctor or pharmacist if any of the side effects get serious.</p><p>Common (may affect up to 1 in 10 people)</p><p>&bull; Headache.&nbsp;</p><p>&bull; Effects on your stomach or gut: diarrhoea, stomach pain, constipation, wind (flatulence).</p><p>&bull; Feeling sick (nausea) or being sick (vomiting).&nbsp;&nbsp; &bull; Benign polyps in the stomach.</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>&bull; Swelling of the feet and ankles.&nbsp; &bull; Disturbed sleep (insomnia).</p><p>&bull; Dizziness, tingling feelings such as &ldquo;pins and needles&rdquo;, feeling sleepy.</p><p>&bull; Spinning feeling (vertigo). &bull; Changes in blood tests that check how the liver is working.</p><p>&bull; Skin rash, lumpy rash (hives) and itchy skin. &bull; Generally feeling unwell and lacking energy.</p><p>Rare (may affect up to 1 in 1,000 people)</p><p>&bull; Blood problems such as a reduced number of white cells or platelets. This can cause weakness, bruising or make infections more likely.</p><p>&bull; Allergic reactions, sometimes very severe, including swelling of the lips, tongue and throat, fever, wheezing. &bull; Low levels of sodium in the blood. This may cause weakness, being sick (vomiting) and cramps.&nbsp; &bull; Feeling agitated, confused or depressed.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&bull; Taste changes.</p><p>&bull; Eyesight problems such as blurred vision.</p><p>&bull; Suddenly feeling wheezy or short of breath (bronchospasm).&nbsp; &bull; Dry mouth.</p><p>&bull; An inflammation of the inside of the mouth.</p><p>&bull; An infection called &ldquo;thrush&rdquo; which can affect the gut and is caused by a fungus.</p><p>&bull; Liver problems, including jaundice which can cause yellow skin, dark urine, and tiredness.</p><p>&bull; Hair loss (alopecia).&nbsp;&nbsp; &bull; Skin rash on exposure to sunshine.</p><p>&bull; Joint pains (arthralgia) or muscle pains (myalgia).</p><p>&bull; Severe kidney problems (interstitial nephritis).&nbsp;&nbsp;&nbsp;&nbsp; &bull; Increased sweating.</p><p>Very rare (may affect up to 1 in 10,000 people)</p><p>&bull; Changes in blood count including agranulocytosis (lack of white blood cells).</p><p>&bull; Aggression.&nbsp;&nbsp; &bull; Seeing, feeling or hearing things that are not there (hallucinations).</p><p>&bull; Severe liver problems leading to liver failure and inflammation of the brain.</p><p>&bull; Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis).</p><p>&bull; Muscle weakness.&nbsp;&nbsp; &bull; Enlarged breasts in men.</p><p>Not known (frequency cannot be estimated from the available data)</p><p>&bull; Inflammation in the gut (leading to diarrhoea).</p><p>&bull; If you are on Emilok for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.</p><p>&bull; Rash, possibly with pain in the joints.</p><p>Emilok may in very rare cases affect the white blood cells leading to immune deficiency.</p><p>If you have an infection with symptoms such as fever with a severely reduced general condition or fever with symptoms of a local infection such as pain in the neck, throat or mouth or difficulties in urinating, you must consult your doctor as soon as possible so that a lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important for you to give information about your medicine at this time.</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep all medicines out of the sight and reach of children. Do not store above 30&deg;C. Store in a dry place. Protect from light . Do not use this medicine after the expiry date which is stated on the carton/blister after EXP. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Emilok contains</p><p>Each Emilok capsule contains 20 mg of omeprazole (the active substance).</p><p>The excipients are: Mannitol, Lactose Monohydrate, Sodium Lauryl Sulphate, Anhydrous Disodium Hydrogen Phosphate, Sucrose, Hypromellose, Methacrylic acid copolymer type C, Sodium Hydroxide, Marcogol 6000, Titanium Dioxide</p><p>Empty hard gelatinous capsule contains:</p><p>Brown cap: Iron oxide red and Titanium dioxide</p><p>Pink body: Iron oxide red and Titanium dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Emilok 20 mg is hard gelatin size '2' capsule with pink colored body printed in black 'EMILOK' and the cap is colored brown printed in white "globalpharma". The capsule contains off white to greyish white spherical pellets. Capsules are supplied in bottle packs of 14 capsules
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Globalpharma Co. LLC, P. O. Box 72168, Dubai, UAE.</p><p>Email: info@globalpharma-sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last updated in March 2017 (12-17).
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي إميلوك&nbsp; على المادة الفعّالة أوميبرازول. وينتمي إلى مجموعة من الأدوية تُسمى: &quot;مثبطات مضخات البروتون&quot;. تعمل هذه الأدوية عن طريق خفض كمية الأحماض التي تنتجها المعدة. يُستَخدَم إميلوك&nbsp; لعلاج الحالات التَّالية:</p><p dir="RTL">الإستخدام مع البالغين:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الجَزْرالمَعِدِيّ المَريئِيّ (الإرتجاع). وهو مرض يحدث نتيجة تسرُّب الأحماض من المعدة إلى المريء (الأنبوب الذي يربط الحَلْق بالمعدة) مما يُسبب الألم والالتهاب والحموضة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القُرَح في الجزء العلوي من الأمعاء (قرحة الإثنا عشر) أو المعدة (قرحة المعدة).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القُرَح الملوثة بعدوى بكتيرية تُسمى:&nbsp; &quot;بكتيريا المَلْوِيَّة البَوَّابية&quot;. إذا كنت مُصابًا بهذه الحالة، فقد يصف لك طبيبك أيضًا مضادات حيوية لعلاج العدوى والسماح بشفاء القرحة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قُرَح ناجمة عن تناوُل أدوية تُسمى: مضادات الالتهاب غير الستيرويدية.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكِن أيضًا أن يُستَخدَم إميلوك&nbsp; لإيقاف تكوُّن القُرَح إذا كنت تتناوُل مضادات الالتهاب غير الستيرويدية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إفراز الأحماض في المعدة نتيجة حدوث نمو في البنكرياس (متلازمة زولينجر إليسون).</p><p dir="RTL">الإستخدام مع الأطفال:</p><p dir="RTL">الأطفال الذين تتجاوز أعمارهم عاماً واحداً ويزنون 10 كجم أو أكثر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الجَزْر (الارتجاع) المَعِدِيّ المَريئِيّ. وهو مرض يحدث نتيجة تسرُّب الأحماض من المعدة إلى المريء (الأنبوب الذي يربط الحَلْق بالمعدة) مما يُسبب الألم والالتهاب والحموضة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الأطفال، يُمكِن أن تشمل الأعراض: عودة محتويات المعدة إلى الفم (ارتجاع)، الإعياء (القيء) ونقص زيادة الوزن.</p><p dir="RTL">الاستخدام مع الأطفال والمراهقين الذين تتجاوز أعمارهم 4 أعوام.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القُرَح الملوثة بعدوى بكتيرية تُسمى: &quot;بكتيريا المَلْوِيَّة البَوَّابية&quot;. إذا كان طفلك مُصابًا بهذه الحالة، فقد يصف له طبيبك أيضًا مضادات حيوية لعلاج العدوى والسماح بشفاء القرحة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول إميلوك&nbsp; في الحالات الآتية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه أوميبرازول أو تجاه أي مكونات أخرى بهذا الدَّواء (المدرجة في القسم: 6).</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية تجاه الأدوية المحتوية على مثبطات مضخة بروتون أخرى (على سبيل المثال: بانتوبرازول، لانسوبرازول، رابيبرازول، إيزوميبرازول).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول دواءً يحتوي على نيلفينافير (يُستَخدَم لعلاج عدوى فيروس نقص المناعة البشري).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول إميلوك إذا كان مما أعلاه ينطبق عليك . إذا لم تكن متأكدًا من هذا، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناوُل إميلوك .</p><p dir="RTL">تحذيرات واحتياطات</p><p dir="RTL">قد يُخفي إميلوك&nbsp; أعراض أمراض أخرى. لذا، إذا حدث لك أيٌّ مما يلي قبل أن تبدأ في تناوُل إميلوك&nbsp; أو أثناء تناوُلك له، فتحدَّث إلى طبيبك فورًا:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فقدت الكثير من الوزن دون سبب وكانت لديك مشاكل في البلع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصِبت بألم في المعدة أو عسر هضم.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا بدأت في تقيؤ طعام أو دم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتبرز برازًا أسود (برازًا ملطخًا بالدَّم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بإسهال شديد أو مستمر؛ إذ ارتبط إميلوك&nbsp; بزيادة طفيفة في الإسهال المُعدي.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل شديدة في الكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك في أي وقت مضى رد فعل جلدية بعد العلاج بدواء يقلل من أحماض المعدة مماثل لإميلوك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت سوف تخضع لفحص دم محدد (كروموجرانين أ ).</p><p dir="RTL">إذا كنت تتناول إميلوك&nbsp; لفترة طويلة الأمد (أكثر من عام واحد) فيرجح أن طبيبك سيضعك تحت المراقبة المنتظمة المستمرة. يجب عليك الإبلاغ عن أي أعراض أو حالات جديدة واستثنائية تعاني منها كلما قمت بالرجوع إلى طبيبك.</p><p dir="RTL">إن تناوُل مثبطات مضخات البروتون مثل إميلوك ، لا سيما على مدار فترة تزيد عن عام واحد، قد يرفع بنسبة طفيفة خطر إصابتك بكسر في الفخذ أو المعصم أو العمود الفقري. أخبر طبيبك إذا كنت مصابًا بهشاشة عظام أو إذا كنت تتناول الكورتيكوستيرويدات (والتي يُمكِن أن تُعزز خطر الإصابة بهشاشة العظام).</p><p dir="RTL">إذا عانيت من طفح على الجلد، وخاصة في المناطق المعرضة لأشعة الشمس فأخبر طبيبك بأسرع وقت ممكن، كما قد تحتاج إلى التوقف عن العلاج بإميلوك. تذكر أيضا أن تذكر أي تأثيرات مرضية مثل الألم في المفاصل.</p><p dir="RTL">الذِئْبَةٌ الحُمَامِيَّةٌ الجِلْدِيَّة دون الحاده (SCLE): ترتبط مثبطات مضخة البروتون مع حالات نادرة جدا من الذِئْبَةٌ الحُمَامِيَّةٌ الجِلْدِيَّة دون الحاده . إذا تم الإصابة بالضرر ، وخاصة في المناطق المعرضة لأشعة الشمس من الجلد، وإذا كان مصحوبا بألم مفصلي ، يجب على المريض طلب المساعدة الطبية على وجه السرعة ، وينبغي على مختصي الرعاية الصحية النظر في إيقاف تناول هذا الدواء. الاصابة بالذِئْبَةٌ الحُمَامِيَّةٌ الجِلْدِيَّة دون الحاده بعد علاج سابق مع مثبط مضخة البروتون قد يزيد من خطر الاصابة بالذِئْبَةٌ الحُمَامِيَّةٌ الجِلْدِيَّة دون الحاده مع مثبطات مضخة البروتون الأخرى.</p><p dir="RTL">الأطفال</p><p dir="RTL">&nbsp;بعض الأطفال الذين يعانون من أمراض مزمنة قد يتطلب علاجهم على المدى الطويل على الرغم من أنه لا ينصح بذلك. لا تعطي هذا الدواء للأطفال الذين تقل أعمارهم عن عام واحد أو تقل أوزانهم عن 10 كجم.</p><p dir="RTL">تناوُل إميلوك&nbsp; مع أدوية أخرى</p><p dir="RTL">أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أي أدوية أخرى، أو قد تناولتها مؤخرًا، أو قد تتناولها. هذا لأن إميلوك&nbsp; قد يُؤثر على طريقة عمل بعض الأدوية كما أن بعض الأدوية قد يكون لها تأثير على إميلوك .</p><p dir="RTL">لا تتناول إميلوك&nbsp; إذا كنت تتناول دواءً يحتوي على نيلفينافير (يُستَخدَم لعلاج عدوى فيروس نقص المناعة البشري).</p><p dir="RTL">أيضًا، أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أيًّا من الأدوية التَّالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول ، إتراكونازول، بوساكونازول أو فوريكونازول (أدوية تُستَخدَم لعلاج العدوى الناجمة عن الفطريات).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسِين (يُستَخدَم لعلاج مشاكل القلب).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديازيبام (يُستَخدَم لعلاج القلق أو ارتخاء العضلات أو في حالات الصرع).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين (يُستَخدَم في حالات الصرع). إذا كنت تتناول فينيتوين، فسيحتاج طبيبك إلى مراقبتك عند بدء تناوُل أوميبرازول أو توقفك عن تناوُله.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لتسييل دمك، مثل: وارفارين أو حاصرات فيتامين &quot;ك&quot; الأخرى. قد يحتاج طبيبك إلى مراقبتك عندما تبدأ في تناوُل أوميبرازول أو تتوقف عن تناوُله.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يُستخدم لعلاج السل)&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أتازانافير (يُستَخدَم لعلاج عدوى فيروس نقص المناعة البشري).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاكروليموس (في حالات زرع الأعضاء).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز (هايبريكوم برفوراتام) (تُستَخدَم لعلاج الاكتئاب الطفيف).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلوستازول (يُستخدم لعلاج العرج المتقطع)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ساكوينافير (يُستخدم لعلاج عدوى فيروس نقص المناعة البشري).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلوبيدوجريل (يُستَخدَم للوقاية من الجلطات الدَّموية [الخَثَرات])&nbsp; &bull; إرلوتينيب (يُستخدم لعلاج السرطان).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات (علاج كيميائي يُستَخدَم بجرعات مرتفعة لعلاج مرض السرطان) - إذا كنت تتناول جرعة مرتفعة من ميثوتريكسات، فقد يُوقِف طبيبك علاجك بإميلوك&nbsp; مؤقتًا.</p><p dir="RTL">إذا وصف لك طبيبك المضادات الحيوية أموكسيسيلين وكلاريثرومايسين إلى جانب أوميبرازول لعلاج القرح الناجمة عن عدوى بكتيريا المَلْوِيَّة البَوَّابية، فمن المهم للغاية أن تخبر طبيبك بشأن أيَّة أدوية أخرى تتناولها.</p><p dir="RTL">تناوُل إميلوك&nbsp; مع الأطعمة والمشروبات: يُمكِنك تناوُل الكبسولات مع الطعام أو على معدة فارغة (انظر القسم 3 ).</p><p dir="RTL">الحمل والرضاعة الطبيعية والإخصاب :</p><p dir="RTL">إذا كنتِ حاملا أو مرضعا ، أو أعتقدت أنك قد تكون حاملا أو تخططين للحمل ، إسألي طبيبك أو الصيدلي الخاص بك للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">يفرز أوميبرازول في حليب الأم ولكن ليس من المحتمل أن يؤثر على الطفل عندما يتم تناول الجرعات العلاجية. طبيبك سوف يقررما إذا كان يمكنك أن تتناولي&nbsp; إميلوك إذا كنت مرضعا.</p><p dir="RTL">القيادة واستخدام الآلات:</p><p dir="RTL">من غير المُرجَّح أن يُؤثر إميلوك&nbsp; على قدرتك على القيادة أو استخدام أي أدوات أو آلات. قد تحدث تأثيرات جانبية مثل: الدوخة والاضطرابات البصرية (انظر قسم: 4). لا تقم بالقيادة أو بتشغيل الآلات إذا أثر عليك العقار.</p><p dir="RTL">يحتوي إميلوك على لاكتوز وسكروز</p><p dir="RTL">إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل تناول هذا المستحضر الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناوَل دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مُراجعة طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التَّناوُل. سيُخبرك طبيبك بعدد الكبسولات التي ستتناولها، وبمدة تناوُلك لها. سيعتمد هذا على حالتك وعُمْرك.</p><p dir="RTL">فيما يلي الجرعات المعتادة.</p><p dir="RTL">البالغون: لعلاج أعراض مرض الجزر المعدي المريئي مثل: الحموضة والارتجاع الحمضي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وجد طبيبك أن أنبوب الغذاء (المَرِيء) لديك قد تعرَّض لتلف طفيف، تكون الجرعة المُوصى بها 20 ملجم مرة واحدة يوميًّا لمدة 4 - 8 أسابيع. قد يخبرك طبيبك بتناوُل جرعة قدرها 40 ملجم لمدة 8 أسابيع إضافية إذا لم يتعافى المريء لديك بعد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها بمجرد تعافي المريء هي 10 ملجم أوميبرازول مرة واحدة يوميًّا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يتعرَّض المريء لديك لتلف، تكون الجرعة المُعتادة 10 ملجم أوميبرازول مرة واحدة يوميًّا.</p><p dir="RTL">لعلاج قُرَح الجزء العلوي من الأمعاء (قرحة الإثنا عشر):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي 20 ملجم مرة واحدة يوميًّا لمدة أسبوعين. قد يخبرك طبيبك بتناوُل الجرعة نفسها لأسبوعين إضافيين إذا لم تشفى القرحة لديك بعد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تشفى القُرَح بشكل تام، فيُمكِن زيادة الجرعة إلى 40 ملجم مرة واحدة يوميًّا لمدة 4 أسابيع.</p><p dir="RTL">لعلاج قُرَح المعدة:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي 20 ملجم مرة واحدة يوميًّا لمدة 4 أسابيع. قد يخبرك طبيبك بتناوُل الجرعة نفسها لمدة 4 أسابيع إضافية إذا لم تشفى القرحة لديك بعد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تشفى القُرَح بشكل تام، فيُمكِن زيادة الجرعة إلى 40 ملجم مرة واحدة يوميًّا لمدة 8 أسابيع.</p><p dir="RTL">للوقاية من عودة قُرَح الإثنا عشر والمعدة مرة أخرى:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي 10 ملجم أو 20 ملجم أوميبرازول مرة واحدة يوميًّا. قد يُزيد طبيبك الجرعة إلى&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40 ملجم مرة واحدة يوميًّا.</p><p dir="RTL">لعلاج قُرَح الإثنا عشر والمعدة الناجمة عن العلاج بمضادات الالتهاب غير الستيرويدية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي 20 ملجم مرة واحدة يوميًّا لمدة من 4-8 أسابيع.</p><p dir="RTL">للوقاية من قُرَح الإثنا عشر والمعدة إذا كنت تتناول مضادات الالتهاب غير الستيرويدية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي 20 ملجم مرة واحدة يوميًّا.</p><p dir="RTL">لعلاج القُرَح الناجمة عن عدوى بكتيريا المَلْوِيَّة البَوَّابية ومنع عودتها:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي 20 ملجم من أوميبرازول مرتين يوميًّا لمدة أسبوع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيخبرك طبيبك أيضًا بتناوُل مضادين حيويين من بين أموكسيسيلين، وكلاريثرومايسين، وميترونيدازول.</p><p dir="RTL">لعلاج فرط الأحماض في المعدة نتيجة حدوث نمو في البنكرياس (متلازمة زولينجر إليسون):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي 60 ملجم يوميًّا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بتعديل الجرعة وفقًا لاحتياجاتك، وسيقرر أيضًا مدة احتياجك لتناوُل الدواء.</p><p dir="RTL">الأطفال والمراهقون:</p><p dir="RTL">&nbsp;لعلاج أعراض مرض الجَزْر المَعِدِي المَريئِيّ مثل الحموضة والارتجاع الحمضي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكِن للأطفال الذين تتجاوز أعمارهم عامًا واحدًا، وتتجاوز أوزانهم 10 كجم تناوُل أوميبرازول. تعتمد جرعة الأطفال على وزن الطفل، وسيقرر الطبيب الجرعة الملائمة.</p><p dir="RTL">لعلاج القُرَح الناجمة عن عدوى بكتيريا المَلْوِيَّة البَوَّابية ومنع عودتها:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكِن للأطفال الذين تتجاوز أعمارهم 4 أعوام تناوُل أوميبرازول. تعتمد جرعة الأطفال على وزن الطفل، وسيقرر الطبيب الجرعة الملائمة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيصف لك طبيبك أيضًا مضادين حيويين هما: أموكسيسيلين وكلاريثرومايسين لعلاج طفلك.</p><p dir="RTL">تناوُل الدَّواء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُوصى بتناوُل الكبسولات في الصباح.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكِنك تناوُل الكبسولات مع الطعام أو على معدة فارغة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الكبسولات كاملة مع نصف كوب من الماء. لا تمضغ الكبسولات أو تسحقها. هذا لأن الكبسولات تحتوي على حبيبات مُغلَّفة تمنع الدَّواء من التَّحلل بواسطة الأحماض الموجودة في معدتك. من المهم عدم إتلاف الحبيبات.</p><p dir="RTL">ماذا تفعل إذا واجهت أنت أو طفلك صعوبة في ابتلاع الكبسولات؟</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا واجهت أنت أو طفلك صعوبة في ابتلاع الكبسولات:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افتح الكبسولات وابتلع المحتويات مباشرةً مع نصف كوب من الماء أو ضع المحتويات في كوب من المياه المقطرة (غير الغازية)، أو أي عصير فواكه حمضية (على سبيل المثال: التفاح أو البرتقال أو الأناناس) أو صلصة التفاح.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرِّك الخليط دائمًا قبل شربه مباشرةً (لا يكون الخليط صافيًا). ثم اشرب الخليط مباشرةً أو في غضون 30 دقيقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للتَّأكد من أنك قد شربت الدَّواء بالكامل، اشطف الكوب جيدًا بنصف كوب من الماء واشربه. لا تستخدم اللبن أو المياه الغازية. تحتوي القطع الصلبة على الدَّواء، فلا تقم بمضغها أو سحقها.</p><p dir="RTL">إذا تناوُلت كمية أكثر مما يجب من إميلوك</p><p dir="RTL">إذا تناولت كمية من إميلوك&nbsp; أكثر من التي وصفها لك طبيبك، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك فورًا.</p><p dir="RTL">إذا نسيت تناوُل إميلوك :</p><p dir="RTL">إذا نسيت تناوُل إحدى الجُرعات، فتناوَلها بمُجرد تذكُّرك لها. ومع ذلك، إذا كان قد حان الوقت تقريبًا لتناوُل الجرعة التالية، فتجاوَز الجُرعة التي نسيتها. لا تتناول جرعة مضاعفة لتعويض جرعة نسيتها.</p><p dir="RTL">إذا توقفت عن تناوُل إميلوك :</p><p dir="RTL">لا تتوقف عن تناول إميلوك بدون استشاراة طبيبك أو الصيدلي الخاص بك .</p><p dir="RTL">&nbsp;إذا كانت لديك أية أسئلة إضافية حول استخدام هذا المستحضر، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">. التأثيرات الجانبية المُحتملة</p><p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء تأثيرات جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">إذا لاحظت أيًّا من التأثيرات الجانبية التَّالية الخطيرة والنادرة توقف عن تناوُل إميلوك واتصل بطبيبك في الحال:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيزًا مفاجئًا بالصدر، تورُّم الشفتين واللسان والحَلْق أو الجسم، أو طفحًا جلديًّا، وإغماء أو صعوبات في البلع (تفاعلات حساسية شديدة).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد مع ظهور بثور عليه أو تقشُّره. قد تكون هناك أيضًا بثور شديدة ونزيف شديد في الشفتين والعينين والفم والأنف والأعضاء التَّناسلية. قد تكون هذه &quot;متلازمة ستيفنز جونسون&quot; أو &quot;انحلال البشرة النخري التَّسَمُّمِيّ&quot;.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد والبول الداكن وتعبًا مما قد يكون أعراضًا تُشير إلى وجود مشاكل بالكبد.</p><p dir="RTL">التأثيرات الجانبية الأخرى محتملة الحدوث مدرجة أدناه في مجموعات وفقًا لمعدل تكرارها.</p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا أصبحت أي من التأثيرات الجانبية خطيرة.</p><p dir="RTL">شائعة (قد تُؤثر على ما يصل إلى شخص واحد من كل 10&nbsp;أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التأثيرات على المعدة أو الأمعاء: إسهال، ألم بالمعدة، إمساك، ريح (انتفاخ البطن بالغازات).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء (غثيان) أو إعياء (قيء).&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زوائد لحميه حميدة في المعدة.&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">غير شائعة (قد تؤثر في ما يصل إلى شخص واحد من كل 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم القدمين والكاحلين.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في النوم (أرق).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة، شعور بالوخز مثل: &quot;وخز [الإبر أو المسامير]&quot;، شعور بالنُّعاس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوران (دوار).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في اختبارات الدَّم التي تفحص كيفية عمل الكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، طفح جلدي عقدي (شرى)، حكة بالجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور عام بالإعياء ونقص الطاقة.</p><p dir="RTL">نادرة (قد تؤثر في ما يصل إلى شخص واحد من بين كل 1000 شخص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالدَّم مثل انخفاض عدد الخلايا البيضاء أو الصفائح الدَّموية. يُمكِن أن يُسَبب هذا ضعفًا أو تكدُّمًا أو يزيد احتمالية الإصابة بعدوى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية، تكون في بعض الأحيان شديدة جدًّا، وتشمل: تورُّم الشفتين واللسان والحلق، وحُمى، وأزيزًا بالصدر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصوديوم في الدَّم. قد يُسبب هذا ضعفًا وإعياء (قيئًا) وتقلصات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالهياج أو الارتباك أو الاكتئاب.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات بحاسة التَّذوق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بصرية مثل عدم وضوح الرؤية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور مفاجئ بأزيز في الصدر أو ضيق بالتنفس (تشنُّج قصبي).&nbsp; &bull; جفاف الفم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب داخل الفم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى تُسمى: &quot;قلاع&quot; يُمكِن أن تُؤثر على الأمعاء وتنتج عن أحد الفطريات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الكبد، بما في ذلك اليرقان الذي قد يُسبب اصفرار الجلد والبول الداكن والتَّعب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر (الثعلبة).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي عند التعرُّض لأشعة الشمس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام بالمفاصل أو آلام بالعضلات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الكُلى الشديدة (التهاب الكلية الخلالي).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التّعرق.</p><p dir="RTL">نادرة جدًّا (قد تؤثر في ما يصل إلى شخص واحد من بين كل 10000 شخص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في تعداد خلايا الدَّم بما في ذلك ندرة خلايا المحببات (نقص خلايا الدَّم البيضاء).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوانية.&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أو سماع أو الإحساس بأشياء غير موجودة (هلَاوِس).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الكبد الشديدة التي تُؤدي إلى الفشل الكبدي والتهاب المخ.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور مفاجئ لطفح جلدي شديد أو بثور أو تقشُّر بالجلد. قد يكون هذا مصحوبًا بحُمى مرتفعة وآلام بالمفاصل (احمرار متعدد الأشكال، متلازمة ستيفنز جونسون، انحلال البشرة النخري التَّسَمُّمِيّ).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخُّم الثّدي لدى الرجال.</p><p dir="RTL">غير معروفة ( نسبة تكرارها غير معروفة من البيانات المتاحة )</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بالأمعاء (يُؤدي إلى الإسهال).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول إميلوك&nbsp; منذ أكثر من ثلاثة أشهر، فقد تهبط مستويات الماغنسيوم في دمك. يُمكِن ملاحظة انخفاض مستويات الماغنسيوم في صورة إرهاق أو تقلصات عضلية لا إرادية، أو توَهان، أو تشنجات، أو دوخة، أو ارتفاع لمعدل ضربات القلب. إذا أُصِبت بأي من هذه الأعراض، فيُرجى إخبار طبيبك فورًا. يُمكِن أيضًا أن يُؤدي انخفاض مستويات الماغنسيوم إلى انخفاض في مستويات البوتاسيوم أو الكالسيوم بالدَّم. قد يقرر طبيبك إجراء اختبارات دم منتظمة؛ لمراقبة مستويات الماغنسيوم لديك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، وربما يعانون من آلام في المفاصل.</p><p dir="RTL">قد يُؤثر إميلوك&nbsp; في حالات شديدة الندرة على خلايا الدَّم البيضاء مما يُؤدي إلى نقص المناعة. إذا كنت مصابًا بعدوى</p><p dir="RTL">مصحوبة بأعراض مثل: حُمى مصحوبة بضعف عام وشديد أو حُمى مصحوبة بأعراض عدوى موضعية مثل: ألم في</p><p dir="RTL">الرقبة أو الحَلْق أو الفم أو صعوبات في التبوُّل، فيجب عليك استشارة طبيبك بأسرع ما يُمكِن حتى يتم استبعاد وجود</p><p dir="RTL">نقص في خلايا الدَّم البيضاء (ندرة خلايا المحببات) عن طريق إجراء اختبار للدَّم. من المهم بالنسبة لك إعطاء معلومات</p><p dir="RTL">عن دوائك في هذا الوقت.</p><p dir="RTL">إذا لاحظت أي تأثيرات جانبية ، قم بإخبار طبيبك المعالج أو الصيدلي الخاص بك. وهذا يشمل أي تأثيرات جانبية محتملة</p><p dir="RTL">غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تحفظ الأدوية بعيدا عن متناول الأطفال ونظرهم. يحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية في مكان جاف بعيدا عن الضوء. لا يستعمل إميلوك بعد انقضاء تاريخ الصلاحية المدون على الشريط وعلى العبوة بعد كلمة EXP. لا ينبغي التخلص من الأدوية في المياه العادمة أو النفايات المنزلية . إسأل الصيدلي الخاص بك عن الطريقة المناسبة للتخلص من الأدوية التي لم تعد بحاجة إليها . فمن شأن هذه الإجراءات حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تحتوي كل كبسولة إميلوك على 20 ملجم من أوميبرازول (المادة الفعَّالة).</p><p dir="RTL">السواغات هي: مانيتول ، لاكتوز احادي الهيدرات ، كبريتات لوريل الصوديوم، فوسفات هيدروجينية&nbsp; ثنائية</p><p dir="RTL">الصوديوم لامائية ، سكروز ، هايبروميلوز ، حمض ميثاكريليك كوبوليمر نوع C ، هيدروكسيد الصوديوم&nbsp; ،&nbsp;</p><p dir="RTL">ماركوجول 6000 ، ثنائي أكسيد التيتانيوم</p><p dir="RTL">كبسولات جيلاتينية صلبة فارغة تتكون من :</p><p dir="RTL">غطاء الكبسولة البني : أكسيد الحديد الأحمر ، ثنائي أكسيد التيتانيوم</p><p dir="RTL">جسم الكبسولة الوردي : أكسيد الحديد الأحمر ، ثنائي أكسيد التيتانيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إميلوك 20 ملجم هو كبسولات جيلاتينية صلبة ، حجم رقم 2 ، وهي ذات جسم وردي مطبوع عليها بالأسود&nbsp; EMILOK&nbsp; وغطاء بني مطبوع عليه بالأبيض&nbsp; globalpharma&nbsp;&nbsp; .</p><p dir="RTL">تحتوي الكبسولات على حبيبات كروية ذات لون أبيض مصفر يميل إلى الأبيض الرمادي .</p><p dir="RTL">تتوفر الكبسولات في عبوات بلاستيكية تحتوي على 14 كبسولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق وجهة التصنيع:</p><p dir="RTL">شركة جلوبال فارما ذ.م.م. ، ص.ب. 72168 ، دبي ، الامارات العربية المتحدة .</p><p dir="RTL">البريد الإلكتروني:&nbsp; info@globalpharma-sanofi.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم آخر تحديث لهذه النشرة في مارس2017 (12-17)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Emilok 20 mg capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 20 mg omeprazole.
Excipient(s) with known effect
Each capsule contains sucrose 30 mg and lactose monohydrate 15 mg. 
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsule, hard 
Emilok 20 mg is hard gelatin size '2' capsule with pink colored body printed in black
'EMILOK' and the cap is colored brown printed in white "globalpharma".
The capsule contains off white to greyish white spherical pellets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Emilok capsules are indicated in:</p><p><u>Adults</u></p><p>&bull; Treatment of duodenal ulcers</p><p>&bull; Prevention of relapse of duodenal ulcers</p><p>&bull; Treatment of gastric ulcers</p><p>&bull; Prevention of relapse of gastric ulcers</p><p>&bull; In combination with appropriate antibiotics,&nbsp;<em>Helicobacter pylori (H. pylori)</em>&nbsp;eradication in peptic ulcer disease</p><p>&bull; Treatment of NSAID-associated gastric and duodenal ulcers</p><p>&bull; Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk</p><p>&bull; Treatment of reflux oesophagitis</p><p>&bull; Long-term management of patients with healed reflux oesophagitis</p><p>&bull; Treatment of symptomatic gastro-oesophageal reflux disease</p><p>&bull; Treatment of Zollinger-Ellison syndrome</p><p><u>Paediatric use</u></p><p><em><u>Children over 1 year of age and &ge; 10 kg</u></em></p><p>&bull; Treatment of reflux oesophagitis</p><p>&bull; Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease</p><p><em><u>Children and adolescents over 4 years of age</u></em></p><p>&bull; In combination with antibiotics in treatment of duodenal ulcer caused by&nbsp;<em>H. pylori</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em><u>Adults</u></em></p><p><em>Treatment of duodenal ulcers</em></p><p>The recommended dose in patients with an active duodenal ulcer is Emilok 20 mg once daily. In most patients healing occurs within two weeks. For those patients who may not be fully healed after the initial course, healing usually occurs during a further two weeks treatment period. In patients with poorly responsive duodenal ulcer Emilok 40 mg once daily is recommended and healing is usually achieved within four weeks.</p><p><em>Prevention of relapse of duodenal ulcers</em></p><p>For the prevention of relapse of duodenal ulcer in&nbsp;<em>H. pylori</em>&nbsp;negative patients or when&nbsp;<em>H. pylori</em>&nbsp;eradication is not possible the recommended dose is Emilok 20 mg once daily. In some patients a daily dose of 10 mg may be sufficient. In case of therapy failure, the dose can be increased to 40 mg.</p><p><em>Treatment of gastric ulcers</em></p><p>The recommended dose is Emilok 20 mg once daily. In most patients healing occurs within four weeks. For those patients who may not be fully healed after the initial course, healing usually occurs during a further four weeks treatment period. In patients with poorly responsive gastric ulcer Emilok 40 mg once daily is recommended and healing is usually achieved within eight weeks.</p><p><em>Prevention of relapse of gastric ulcers</em></p><p>For the prevention of relapse in patients with poorly responsive gastric ulcer the recommended dose is Emilok 20 mg once daily. If needed the dose can be increased to Emilok 40 mg once daily.</p><p><em>H. pylori eradication in peptic ulcer disease</em></p><p>For the eradication of&nbsp;<em>H. pylori</em>&nbsp;the selection of antibiotics should consider the individual patient&#39;s drug tolerance, and should be undertaken in accordance with national, regional and local resistance patterns and treatment guidelines.</p><p>&bull; Emilok 20 mg + clarithromycin 500 mg + amoxicillin 1,000 mg, each twice daily for one week, or</p><p>&bull; Emilok 20 mg + clarithromycin 250 mg (alternatively 500 mg) + metronidazole 400 mg (or 500 mg or tinidazole 500 mg), each twice daily for one week or</p><p>&bull; Emilok 40 mg once daily with amoxicillin 500 mg and metronidazole 400 mg (or 500 mg or tinidazole 500 mg), both three times a day for one week.</p><p>In each regimen, if the patient is still&nbsp;<em>H. pylori</em>&nbsp;positive, therapy may be repeated.</p><p><em>Treatment of NSAID-associated gastric and duodenal ulcers</em></p><p>For the treatment of NSAID<em>-</em>associated gastric and duodenal ulcers, the recommended dose is Emilok 20 mg once daily. In most patients healing occurs within four weeks. For those patients who may not be fully healed after the initial course, healing usually occurs during a further four weeks treatment period.</p><p><em>Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk</em></p><p>For the prevention of NSAID<em>-</em>associated gastric ulcers or duodenal ulcers in patients at risk (age&gt; 60, previous history of gastric and duodenal ulcers, previous history of upper GI bleeding) the recommended dose is Emilok 20 mg once daily.</p><p><em>Treatment of reflux oesophagitis</em></p><p>The recommended dose is Emilok 20 mg once daily. In most patients healing occurs within four weeks. For those patients who may not be fully healed after the initial course, healing usually occurs during a further four weeks treatment period.</p><p>In patients with severe oesophagitis Emilok 40 mg once daily is recommended and healing is usually achieved within eight weeks.</p><p><em>Long-term management of patients with healed reflux oesophagitis</em></p><p>For the long-term management of patients with healed reflux oesophagitis the recommended dose is omeprazole 10 mg once daily. If needed, the dose can be increased to Emilok 20-40 mg once daily.</p><p><em>Treatment of symptomatic gastro-oesophageal reflux disease</em></p><p>The recommended dose is Emilok 20 mg daily. Patients may respond adequately to 10 mg daily, and therefore individual dose adjustment should be considered.</p><p>If symptom control has not been achieved after four weeks treatment with Emilok 20 mg daily, further investigation is recommended.</p><p><em>Treatment of Zollinger-Ellison syndrome</em></p><p>In patients with Zollinger-Ellison syndrome the dose should be individually adjusted and treatment continued as long as clinically indicated. The recommended initial dose is omeprazole 60 mg daily. All patients with severe disease and inadequate response to other therapies have been effectively controlled and more than 90% of the patients maintained on doses of omeprazole 20-120 mg daily. When dose exceed omeprazole 80 mg daily, the dose should be divided and given twice daily.</p><p><em><u>Paediatric population</u></em></p><p><em><u>Children over 1 year of age and &ge; 10 kg</u></em></p><p><em>Treatment of reflux oesophagitis</em></p><p><em>Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease</em></p><p>The posology recommendations are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Age</p></td><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Posology</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 1 year of age</p></td><td style="vertical-align:top"><p>10-20 kg</p></td><td style="vertical-align:top"><p>10 mg once daily. The dose can be increased to 20 mg once daily if needed</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 2 years of age</p></td><td style="vertical-align:top"><p>&gt; 20 kg</p></td><td style="vertical-align:top"><p>20 mg once daily. The dose can be increased to 40 mg once daily if needed</p></td></tr></tbody></table><p><em>Reflux oesophagitis</em>: The treatment time is 4-8 weeks.</p><p><em>Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease:</em>&nbsp;The treatment time is 2&ndash;4 weeks. If symptom control has not been achieved after 2&ndash;4 weeks the patient should be investigated further.</p><p><em><u>Children and adolescents over 4 years of age</u></em></p><p><em>Treatment of duodenal ulcer caused by H. pylori</em></p><p>When selecting appropriate combination therapy, consideration should be given to official national, regional and local guidance regarding bacterial resistance, duration of treatment (most commonly 7 days but sometimes up to 14 days), and appropriate use of antibacterial agents.</p><p>The treatment should be supervised by a specialist.</p><p>The posology recommendations are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Posology</p></td></tr><tr><td style="vertical-align:top"><p>15&ndash;30 kg</p></td><td style="vertical-align:top"><p>Combination with two antibiotics: Omeprazole 10 mg, amoxicillin 25 mg/kg body weight and clarithromycin 7.5 mg/kg body weight are all administered together two times daily for one week.</p></td></tr><tr><td style="vertical-align:top"><p>31&ndash;40 kg</p></td><td style="vertical-align:top"><p>Combination with two antibiotics: Emilok 20 mg, amoxicillin 750 mg and clarithromycin 7.5 mg/kg body weight are all administered two times daily for one week.</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 40 kg</p></td><td style="vertical-align:top"><p>Combination with two antibiotics: Emilok 20 mg, amoxicillin 1 g and clarithromycin 500 mg are all administered two times daily for one week.</p></td></tr></tbody></table><p><em><u>Special populations</u></em></p><p><em>Renal impairment</em></p><p>Dose adjustment is not needed in patients with impaired renal function (see section 5.2).</p><p><em>Hepatic impairment</em></p><p>In patients with impaired hepatic function a daily dose of 10&ndash;20 mg may be sufficient (see section 5.2).</p><p><em>Elderly</em></p><p>Dose adjustment is not needed in the elderly (see section 5.2).</p><p><u>Method of administration</u></p><p>It is recommended to take Emilok capsules in the morning, swallowed whole with half a glass of water. The capsules must not be chewed or crushed.</p><p><em>For patients with swallowing difficulties and for children who can drink or swallow semi-solid food</em></p><p>Patients can open the capsule and swallow the contents with half a glass of water or after mixing the contents in a slightly acidic fluid e.g. fruit juice or applesauce, or in non-carbonated water. Patients should be advised that the dispersion should be taken immediately (or within 30 minutes) and always be stirred just before drinking and rinsed down with half a glass of water.</p><p>Alternatively, patients can suck the capsule and swallow the pellets with half a glass of water. The enteric-coated pellets must not be chewed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients listed in section 6.1.
Omeprazole like other proton pump inhibitors (PPIs) must not be used concomitantly with nelfinavir (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment may alleviate symptoms and delay diagnosis.</p><p>Co-administration of atazanavir with proton pump inhibitors is not recommended (see section 4.5). If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g virus load) is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; omeprazole 20 mg should not be exceeded.</p><p>Omeprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B<sub>12</sub>&nbsp;(cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B<sub>12</sub>&nbsp;absorption on long-term therapy.</p><p>Omeprazole is a CYP2C19 inhibitor. When starting or ending treatment with omeprazole, the potential for interactions with drugs metabolised through CYP2C19 should be considered. An interaction is observed between clopidogrel and omeprazole (see section 4.5). The clinical relevance of this interaction is uncertain. As a precaution, concomitant use of omeprazole and clopidogrel should be discouraged.</p><p>Severe hypomagnesaemia has been reported in patients treated with proton pump inhibitors (PPIs) like omeprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g. diuretics), healthcare professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10-40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p><u>Subacute cutaneous lupus erythematosus (SCLE)</u></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Emilok. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p><u>Interference with laboratory tests</u></p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, omeprazole treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p><p>Some children with chronic illnesses may require long-term treatment although it is not recommended.</p><p>Emilok contains lactose and sucrose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as&nbsp;<em>Salmonella</em>&nbsp;and&nbsp;<em>Campylobacter</em>&nbsp;and, in hospitalised patients, possibly also&nbsp;<em>Clostridium difficile</em>&nbsp;(see section 5.1).</p><p>As in all long-term treatments, especially when exceeding a treatment period of 1 year, patients should be kept under regular surveillance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of omeprazole on the pharmacokinetics of other active substances</u></p><p><em><u>Active substances with pH dependent absorption</u></em></p><p>The decreased intragastric acidity during treatment with omeprazole might increase or decrease the absorption of active substances with a gastric pH dependent absorption.</p><p><em>Nelfinavir, atazanavir</em></p><p>The plasma levels of nelfinavir and atazanavir are decreased in case of co-administration with omeprazole.</p><p>Concomitant administration of omeprazole with nelfinavir is contraindicated (see section 4.3). Co-administration of omeprazole (40 mg once daily) reduced mean nelfinavir exposure by ca. 40% and the mean exposure of the pharmacologically active metabolite M8 was reduced by ca. 75 &ndash;90%. The interaction may also involve CYP2C19 inhibition.</p><p>Concomitant administration of omeprazole with atazanavir is not recommended (see section 4.4). Concomitant administration of omeprazole (40 mg once daily) and atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a 75% decrease of the atazanavir exposure. Increasing the atazanavir dose to 400 mg did not compensate for the impact of omeprazole on atazanavir exposure. The co-administration of omeprazole (20 mg once daily) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared to atazanavir 300 mg/ritonavir 100 mg once daily.</p><p><em>Digoxin</em></p><p>Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10%. Digoxin toxicity has been rarely reported. However caution should be exercised when omeprazole is given at high doses in elderly patients. Therapeutic drug monitoring of digoxin should be then be reinforced.</p><p><em>Clopidogrel</em></p><p>Results from studies in healthy subjects have shown a pharmacokinetic (PK)/pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and omeprazole (80 mg p.o. daily) resulting in a decreased exposure to the active metabolite of clopidogrel by an average of 46% and a decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 16%.</p><p>Inconsistent data on the clinical implications of a PK/PD interaction of omeprazole in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution, concomitant use of omeprazole and clopidogrel should be discouraged (see section 4.4).</p><p><em>Other active substances</em></p><p>The absorption of posaconazole, erlotinib, ketoconazole and itraconazole is significantly reduced and thus clinical efficacy may be impaired. For posaconazole and erlotinib concomitant use should be avoided.</p><p><em><u>Active substances metabolised by CYP2C19</u></em></p><p>Omeprazole is a moderate inhibitor of CYP2C19, the major omeprazole metabolising enzyme. Thus, the metabolism of concomitant active substances also metabolised by CYP2C19, may be decreased and the systemic exposure to these substances increased. Examples of such drugs are R-warfarin and other vitamin K antagonists, cilostazol, diazepam and phenytoin.</p><p><em>Cilostazol</em></p><p>Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased C<sub>max&nbsp;</sub>and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by 29% and 69% respectively.</p><p><em>Phenytoin</em></p><p>Monitoring phenytoin plasma concentration is recommended during the first two weeks after initiating omeprazole treatment and, if a phenytoin dose adjustment is made, monitoring and a further dose adjustment should occur upon ending omeprazole treatment.</p><p><em><u>Unknown mechanism</u></em></p><p><em>Saquinavir</em></p><p>Concomitant administration of omeprazole with saquinavir/ritonavir resulted in increased plasma levels up to approximately 70% for saquinavir associated with good tolerability in HIV-infected patients.</p><p><em>Tacrolimus</em></p><p>Concomitant administration of omeprazole has been reported to increase the serum levels of tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function (creatinine clearance) should be performed, and dosage of tacrolimus adjusted if needed.</p><p><em>Methotrexate</em></p><p>When given together with proton-pump inhibitors, methotrexate levels have been reported to increase in some patients. In high-dose methotrexate administration a temporary withdrawal of omeprazole may need to be considered.</p><p><u>Effects of other active substances on the pharmacokinetics of omeprazole</u></p><p><em><u>Inhibitors of CYP2C19 and/or CYP3A4</u></em></p><p>Since omeprazole is metabolised by CYP2C19 and CYP3A4, active substances known to inhibit CYP2C19 or CYP3A4 (such as clarithromycin and voriconazole) may lead to increased omeprazole serum levels by decreasing omeprazole&#39;s rate of metabolism. Concomitant voriconazole treatment resulted in more than doubling of the omeprazole exposure. As high doses of omeprazole have been well-tolerated adjustment of the omeprazole dose is not generally required. However, dose adjustment should be considered in patients with severe hepatic impairment and if long-term treatment is indicated.</p><p><em><u>Inducers of CYP2C19 and/or CYP3A4</u></em></p><p>Active substances known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St John&#39;s wort) may lead to decreased omeprazole serum levels by increasing omeprazole&#39;s rate of metabolism</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Results from three prospective epidemiological studies (more than 1000 exposed outcomes) indicate no adverse effects of omeprazole on pregnancy or on the health of the foetus/newborn child. Omeprazole can be used during pregnancy.</p><p><u>Breast-feeding</u></p><p>Omeprazole is excreted in breast milk but is not likely to influence the child when therapeutic doses are used.</p><p><u>Fertility</u></p><p>Animal studies with the racemic mixture omeprazole, given by oral administration do not indicate effects with respect to fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Emilok is not likely to affect the ability to drive or use machines. Adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most common side effects (1-10% of patients) are headache, abdominal pain, constipation, diarrhoea, flatulence and nausea/vomiting.</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse drug reactions have been identified or suspected in the clinical trials programme for omeprazole and post-marketing. None was found to be dose-related. Adverse reactions listed below are classified according to frequency and System Organ Class (SOC). Frequency categories are defined according to the following convention: Very common (&ge; 1/10), Common (&ge; 1/100 to &lt; 1/10), Uncommon (&ge; 1/1,000 to &lt; 1/100), Rare (&ge; 1/10,000 to &lt; 1/1,000), Very rare (&lt; 1/10,000), Not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>SOC/frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Leukopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Agranulocytosis, pancytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hypomagnesaemia; severe hypomagnesaemia may result in hypocalcaemia.</p><p>Hypomagnesaemia may also be associated with hypokalaemia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Agitation, confusion, depression</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Aggression, hallucinations</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dizziness, paraesthesia, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Taste disturbance</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Blurred vision</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting, fundic gland polyps (benign)</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Dry mouth, stomatitis, gastrointestinal candidiasis</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Microscopic colitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Increased liver enzymes</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hepatitis with or without jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Hepatic failure, encephalopathy in patients with pre-existing liver disease</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dermatitis, pruritus, rash, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Alopecia, photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Subacute cutaneous lupus erythematosus (see section 4.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Fracture of the hip, wrist or spine</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Muscular weakness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Interstitial nephritis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Malaise, peripheral oedema</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Increased sweating</p></td></tr></tbody></table><p><u>Paediatric population</u></p><p>The safety of omeprazole has been assessed in a total of 310 children aged 0 to 16 years with acid-related disease. There are limited long-term safety data from 46 children who received maintenance therapy of omeprazole during a clinical study for severe erosive oesophagitis for up to 749 days. The adverse event profile was generally the same as for adults in short- as well as in long-term treatment. There are no long-term data regarding the effects of omeprazole treatment on puberty and growth.</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at:</p><p>&nbsp;&bull; <strong>Saudi Arabia:</strong> The National Pharmacovigilance and Drug Safety Centre (NPC) ,</p><p>Fax: +966-11-205-7662, Call NPC at +966-11-2038222, Exts 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000 , E-mail: npc.drug@sfda.gov.sa ,</p><p>Website: www.sfda.gov.sa/npc</p><p>Sanofi in KSA: ksa_pharmacovigilance@sanofi.com, Tel: +966544284797.</p><p>&bull; <strong>Other GCC States:</strong> Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited information available on the effects of overdoses of omeprazole in humans. In the literature, doses of up to 560 mg have been described, and occasional reports have been received when single oral doses have reached up to 2,400 mg omeprazole (120 times the usual recommended clinical dose). Nausea, vomiting, dizziness, abdominal pain, diarrhoea and headache have been reported. Also apathy, depression and confusion have been described in single cases.</p><p>The symptoms described have been transient, and no serious outcome has been reported. The rate of elimination was unchanged (first order kinetics) with increased doses. Treatment, if needed, is symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for acid-related disorders, proton pump inhibitors, ATC code: A02BC01</p><p><u>Mechanism of action</u></p><p>Omeprazole, a racemic mixture of two enantiomers<strong>&nbsp;</strong>reduces gastric acid secretion through a highly targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. It is rapidly acting and provides control through reversible inhibition of gastric acid secretion with once daily dosing.</p><p>Omeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the intracellular canaliculi within the parietal cell, where it inhibits the enzyme H<sup>+</sup>&nbsp;K<sup>+</sup>-ATPase - the acid pump. This effect on the final step of the gastric acid formation process is dose-dependent and provides for highly effective inhibition of both basal acid secretion and stimulated acid secretion, irrespective of stimulus.</p><p><u>Pharmacodynamic effects</u></p><p>All pharmacodynamic effects observed can be explained by the effect of omeprazole on acid secretion.</p><p><em><u>Effect on gastric acid secretion</u></em></p><p>Oral dosing with omeprazole once daily provides for rapid and effective inhibition of daytime and night-time gastric acid secretion with maximum effect being achieved within 4 days of treatment. With omeprazole 20 mg, a mean decrease of at least 80% in 24-hour intragastric acidity is then maintained in duodenal ulcer patients, with the mean decrease in peak acid output after pentagastrin stimulation being about 70% 24 hours after dosing.</p><p>Oral dosing with omeprazole 20 mg maintains an intragastric pH of &ge; 3 for a mean time of 17 hours of the 24-hour period in duodenal ulcer patients.</p><p>As a consequence of reduced acid secretion and intragastric acidity, omeprazole dose-dependently reduces/normalizes acid exposure of the oesophagus in patients with gastro-oesophageal reflux disease.</p><p>The inhibition of acid secretion is related to the area under the plasma concentration-time curve (AUC) of omeprazole and not to the actual plasma concentration at a given time.</p><p>No tachyphylaxis has been observed during treatment with omeprazole.</p><p><em><u>Effect on H. pylori</u></em></p><p><em>H. pylori</em>&nbsp;is associated with peptic ulcer disease, including duodenal and gastric ulcer disease.&nbsp;<em>H. pylori</em>&nbsp;is a major factor in the development of gastritis.&nbsp;<em>H. pylori</em>&nbsp;together with gastric acid are major factors in the development of peptic ulcer disease.&nbsp;<em>H. pylori</em>&nbsp;is a major factor in the development of atrophic gastritis which is associated with an increased risk of developing gastric cancer.</p><p>Eradication of&nbsp;<em>H. pylori</em>&nbsp;with omeprazole and antimicrobials is associated with, high rates of healing and long-term remission of peptic ulcers.</p><p>Dual therapies have been tested and found to be less effective than triple therapies. They could, however, be considered in cases where known hypersensitivity precludes use of any triple combination.</p><p><em><u>Other effects related to acid inhibition</u></em></p><p>During long-term treatment gastric glandular cysts have been reported in a somewhat increased frequency. These changes are a physiological consequence of pronounced inhibition of acid secretion, are benign and appear to be reversible.</p><p>Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with acid-reducing drugs may lead to slightly increased risk of gastrointestinal infections such as&nbsp;<em>Salmonella</em>&nbsp;and&nbsp;<em>Campylobacter</em>&nbsp;and, in hospitalised patients, possibly also&nbsp;<em>Clostridium difficile.</em></p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours. Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p><p>An increased number of ECL cells possibly related to the increased serum gastrin levels, have been observed in some patients (both children and adults) during long term treatment with omeprazole. The findings are considered to be of no clinical significance.</p><p><u>Paediatric population</u></p><p>In a non-controlled study in children (1 to 16 years of age) with severe reflux oesophagitis, omeprazole at doses of 0.7 to 1.4 mg/kg improved oesophagitis level in 90% of the cases and significantly reduced reflux symptoms. In a single-blind study, children aged 0&ndash;24 months with clinically diagnosed gastro-oesophageal reflux disease were treated with 0.5, 1.0 or 1.5 mg omeprazole/kg. The frequency of vomiting/regurgitation episodes decreased by 50% after 8 weeks of treatment irrespective of the dose.</p><p><em><u>Eradication of H. pylori in children</u></em></p><p>A randomised, double blind clinical study (H&eacute;liot study) concluded that omeprazole in combination with two antibiotics (amoxicillin and clarithromycin), was safe and effective in the treatment of&nbsp;<em>H. pylori</em>&nbsp;infection in children age 4 years old and above with gastritis:&nbsp;<em>H. pylori&nbsp;</em>eradication rate: 74.2% (23/31 patients) with omeprazole + amoxicillin + clarithromycin versus 9.4% (3/32 patients) with amoxicillin + clarithromycin. However, there was no evidence of any clinical benefit with respect to dyspeptic symptoms. This study does not support any information for children aged less than 4 years.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Omeprazole and omeprazole magnesium are acid labile and are therefore administered orally as enteric-coated granules in capsules or tablets. Absorption of omeprazole is rapid, with peak plasma levels occurring approximately 1-2 hours after dose. Absorption of omeprazole<strong>&nbsp;</strong>takes place in the small intestine and is usually completed within 3-6 hours. Concomitant intake of food has no influence on the bioavailability. The systemic availability (bioavailability) from a single oral dose of omeprazole is approximately 40%. After repeated once-daily administration, the bioavailability increases to about 60%.</p><p><u>Distribution</u></p><p>The apparent volume of distribution in healthy subjects is approximately 0.3 l/kg body weight. Omeprazole is 97% plasma protein bound.</p><p><u>Biotransformation</u></p><p>Omeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of its metabolism is dependent on the polymorphically expressed CYP2C19, responsible for the formation of hydroxyomeprazole, the major metabolite in plasma. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of omeprazole sulfone. As a consequence of high affinity of omeprazole to CYP2C19, there is a potential for competitive inhibition and metabolic drug-drug interactions with other substrates for CYP2C19. However, due to low affinity to CYP3A4, omeprazole has no potential to inhibit the metabolism of other CYP3A4 substrates. In addition, omeprazole lacks an inhibitory effect on the main CYP enzymes.</p><p>Approximately 3% of the Caucasian population and 15-20% of Asian populations lack a functional CYP2C19 enzyme and are called poor metabolisers. In such individuals the metabolism of omeprazole is probably mainly catalysed by CYP3A4. After repeated once-daily administration of 20 mg omeprazole, the mean AUC was 5 to 10 times higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were also higher, by 3 to 5 times. These findings have no implications for the posology of omeprazole.</p><p><u>Elimination</u></p><p>The plasma elimination half-life of omeprazole is usually shorter than one hour both after single and repeated oral once-daily dosing. Omeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once-daily administration. Almost 80% of an oral dose of omeprazole is excreted as metabolites in the urine, the remainder in the faeces, primarily originating from bile secretion.</p><p>Linearity/non-linearity</p><p>The AUC of omeprazole increases with repeated administration. This increase is dose-dependent and results in a non-linear dose-AUC relationship after repeated administration. This time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by an inhibition of the CYP2C19 enzyme by omeprazole and/or its metabolites (e.g. the sulfone).</p><p>No metabolite has been found to have any effect on gastric acid secretion.</p><p><u>Special populations</u></p><p><em><u>Hepatic impairment</u></em></p><p>The metabolism of omeprazole in patients with liver dysfunction is impaired, resulting in an increased AUC. Omeprazole has not shown any tendency to accumulate with once daily dosing.</p><p><em><u>Renal impairment</u></em></p><p>The pharmacokinetics of omeprazole, including systemic bioavailability and elimination rate, are unchanged in patients with reduced renal function.</p><p><em><u>Elderly</u></em></p><p>The metabolism rate of omeprazole is somewhat reduced in elderly subjects (75-79 years of age).</p><p><em><u>Paediatric population</u></em></p><p>During treatment with the recommended doses to children from the age of 1 year, similar plasma concentrations were obtained as compared to adults. In children younger than 6 months, clearance of omeprazole is low due to low capacity to metabolise omeprazole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastric ECL-cell hyperplasia and carcinoids, have been observed in life-long studies in rats treated with omeprazole. These changes are the result of sustained hypergastrinaemia secondary to acid inhibition. Similar findings have been made after treatment with H<sub>2</sub>-receptor antagonists, proton pump inhibitors and after partial fundectomy. Thus, these changes are not from a direct effect of any individual active substance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The excipients are:</p><p>Mannitol, Lactose Monohydrate, Sodium Lauryl Sulphate, Anhydrous</p><p>Disodium Hydrogen Phosphate, Sucrose, Hypromellose, Methacrylic acid copolymer type C,</p><p>Sodium Hydroxide, Marcogol 6000, Titanium Dioxide</p><p>Empty hard gelatinous capsule contains:</p><p>Brown cap: Iron oxide red and Titanium dioxide</p><p>Pink body: Iron oxide red and Titanium dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in a dry place. Protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE bottle with a white PP twist cap &ldquo;Child Resistant Cap&rdquo; with a desiccant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Globalpharma Co LLC, Lahbab Street, DIP, Jebel Ali, Dubai, UAE.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12th December  2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>